Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 14 of 14 for “"Myeloma patients"”.
-
Improving the Monitoring of Multiple Myeloma Patients Using Blood Based Markers of Disease
Multiple myeloma (MM) is a haematological malignancy characterised by the proliferation of clonal plasma cells in the bone marrow, usually leading to the secretion of a monoclonal immunoglobulin termed the M-protein. Multiple myeloma is a complex disease, and despite great advances in both …
-
Molecular mechanisms of myricetin bulk and nano forms mediating genoprotective and genotoxic effects in lymphocytes from pre-cancerous and myeloma patients
… the lymphocytes from pre-cancerous and multiple myeloma cancer patients compared to those from healthy individuals. Also, to investigate the protective potential of myricetin bulk and nano against the oxidative stress produced in vitro by 2- amino-1-methyl-6 phenylimidazo [4, 5-b] pyridine and …
-
Molecular mechanisms of myricetin bulk and nano forms mediating genoprotective and genotoxic effects in lymphocytes from pre-cancerous and myeloma patients
… the lymphocytes from pre-cancerous and multiple myeloma cancer patients compared to those from healthy individuals. Also, to investigate the protective potential of myricetin bulk and nano against the oxidative stress produced in vitro by 2- amino-1-methyl-6 phenylimidazo [4, 5-b] pyridine and …
-
Investigating biomarkers in clinical samples that are predictive of response in multiple myeloma
Multiple Myeloma is a heterogeneous group of disorders of plasma cell proliferation both genotypically and phenotypically. Thalidomide is an effective treatment for multiple myeloma. However, some patients fail to respond to thalidomide treatment and identifying this cohort may provide better …
-
Bioinformatics pipeline development for analyses of data generated by target capture-based Next-Generation Sequencing, to characterise mutations and the utility of using off-target sequences to detect genomic imbalances in Multiple Myeloma patients.
Greater Multiple Myeloma (MM) genomics understanding is required to improve patient care and outcomes, currently limited by available methods, especially regarding structural variant (SV)/copy number alteration (CNA) detection. This study aimed to exemplify target-capture Next-Generation Sequencing …
-
Combination of Dasatinib and Dexamethasone targets the myeloma plasma cell through its interaction with the bone marrow microenvironment
Dexamethasone therapy has been the backbone of myeloma treatment for the last few decades. Despite advances in chemotherapy, myeloma continues to be incurable and all patients eventually relapse with progressive disease. Cell adhesion mediated drug resistance and a permissive bone marrow …
-
Intron Retention Induced Neoantigen as Biomarkers in Diseases
… IR neoantigen using RNA-Seq data for multiple myeloma patients from the MMRF study. Our results suggested that the IR-neoAg load could serve as a prognosis biomarker, and immunosuppression in the myeloma microenvironment might offset the increasing neoantigen load effect. Thirdly, we …
-
Development and application of novel analytical methods for molecularly targeted cancer therapeutics
… drug resistance mechanisms, and 2) the multiple myeloma drug thalidomide as a pilot study to identify potential correlations between serum drug levels and toxicity/efficacy. Acquired resistance to chemotherapeutics through the over-expression of ABC transport proteins has presented a significant …
-
Characterisation of the mechanisms of tumour-induced dysfunction of clonal T cell expansions in multiple myeloma
Multiple myeloma is a cancer involving malignant plasma cells in the bone marrow. Despite advances in therapy, relapse is inevitable due to residual disease and myeloma remains incurable. New therapies are required to remove residual disease and maintain long term survival. Expanded clones of …
-
Employing T Cells For Antigen Presentation: Role of Ny-Eso-1+ T-Apc Vaccine In Multiple Myeloma
… and an NY-ESO-1 specific T-APC vaccine in myeloma patients may lead to enhanced anti-myeloma efficacy due to improved persistence of the CAR T cells.</p> <p><strong>Materials and Methods</strong>: Using the Sleeping Beauty transposon/transposase system, an NY-ESO-1<sup>+</sup> TCR and CAR …
-
Multiple Myeloma and Its Treatment Alter Peripheral Nervous System Structure and Function
<p><strong>MULTIPLE MYELOMA AND ITS TREATMENT ALTER PERIPHERAL NERVOUS SYSTEM STRUCTURE AND FUNCTION </strong></p> <p>Alyssa Katarina Kosturakis, BA</p> <p>Supervisory Professor: Patrick M. Dougherty, PhD</p> <p>Peripheral neuropathy is among the most deleterious side effects of frontline …
-
Cost utility and budget impact analysis of bortezomib and lenalidomide for the treatment of relapsed/refractory multiple myeloma in the South African public health sector
Multiple myeloma (MM) is the second most common haematologic cancer, accounting for approximately 13% of all blood cancer cases worldwide. The global incidence rate increased by 126% from 1990 to 2016. In South Africa, multiple myeloma accounts for approximately 9% of haematological cancers and …
-
An investigation of the role of ACTN1 in platelet formation and of platelet function in myeloma
… and the acquired prothrombotic state in Multiple Myeloma (MM). Actinin-1 is a widely-expressed actin binding protein but mutations have a tissue-specific impact, causing CMTP, characterised by low platelet count and large platelet size. It was previously shown that mutations in the actin-binding …
-
The art of healing : A journey through cancer : Implications for art therapy
… psychotherapist, who was diagnosed with multiple myeloma seven years ago. Multiple myeloma is cancer of the bone marrow and blood, a medically incurable form of cancer (Mayo Clinic, 1996; Macpherson, 1995). The principles of Holistic Medicine and Arts Medicine provide the theoretical framework. …